# AstraZeneca’s Voydeya recommended for PNH treatment in EU

- Link: https://www.directorstalkinterviews.com/astrazenecas-voydeya-recommended-for-pnh-treatment-in-eu/4121144392
- Published: 2024-02-26T07:40:49+00:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
Voydeya (danicopan) has been recommended for marketing authorisation in the European
Union (EU) as an add-on to ravulizumab or eculizumab for the treatment of adult 
patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic
anaemia. _Voydeya_ is a first-in-class, oral, Factor D inhibitor developed as an
add-on to standard-of-care _Ultomiris_ (ravulizumab) or _Soliris_ (eculizumab) to
address the needs of the approximately 10-20% of patients with PNH who experience
clinically significant extravascular haemolysis (EVH) while treated with a C5 inhibitor.
^(1,2)

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines
Agency (EMA) based its positive opinion on results from the pivotal ALPHA Phase 
III trial. Results from the 12-week primary evaluation period of the trial were 
published in The Lancet Haematology.^(1)

PNH is a rare and severe blood disorder characterised by the destruction of red 
blood cells within blood vessels, known as intravascular haemolysis (IVH), and white
blood cell and platelet activation that can cause thrombosis (blood clots) and result
in organ damage and potentially premature death.^(3-5) Immediate, complete and sustained
terminal complement inhibition by blocking the C5 protein helps reduce symptoms 
and complications, resulting in  improved survival for patients with PNH.^(5-8) 
Approximately 10-20% of people living with PNH who are treated with a C5 inhibitor
experience clinically significant EVH, which can result in continued symptoms of
anaemia and require blood transfusions.^(1-3,9-11)

> **Professor Hubert Schrezenmeier, MD, Medical Director, Institute of Transfusion
> Medicine at The University of Ulm, said**: “C5 inhibition with _Ultomiris_ or 
> _Soliris_ is the standard-of-care in PNH, proven to control IVH and reduce life-
> threatening thrombotic events, yet a small portion of patients may experience 
> clinically significant EVH. In the ALPHA trial, _Voydeya_ as an add-on to _Soliris_
> or _Ultomiris_ increased haemoglobin levels and reduced fatigue, anaemia and transfusion
> dependence. If approved, _Voydeya_ may optimise care for people impacted by this
> burdensome condition while allowing patients to maintain disease control with 
> an established C5 inhibitor.”

> **Marc Dunoyer, Chief Executive Officer, Alexion, said**: “Today’s positive CHMP
> recommendation recognises the promise of _Voydeya_ as an add-on to standard-of-
> care to address signs and symptoms of clinically significant EVH for this small
> subset of patients. As we saw in the pivotal ALPHA Phase III trial, dual complement
> pathway inhibition at Factor D and C5 may be an optimal treatment approach for
> these patients.”

The ALPHA Phase III trial evaluated the efficacy and safety of _Voydeya_ as an add-
on to _Ultomiris_ or _Soliris_ in patients with PNH who experienced clinically significant
EVH. Results showed that _Voydeya_ met the primary endpoint of change in haemoglobin
from baseline to week 12 and all key secondary endpoints, including transfusion 
avoidance and change in Functional Assessment of Chronic Illness Therapy – Fatigue(
FACIT-Fatigue) score.^(1) 

Results from the ALPHA Phase III trial showed _Voydeya_ was generally well tolerated,
and no new safety concerns were identified. In the trial, the most common treatment-
emergent adverse events were headache, nausea, arthralgia and diarrhoea.^(1) 

_Voydeya_ has been granted Breakthrough Therapy designation by the US Food and Drug
Administration and PRIority MEdicines (PRIME) status by the EMA. _Voydeya_ has also
been granted Orphan Drug Designation in the US, EU and Japan for the treatment of
PNH. _Voydeya_ was recently approved in Japan, and regulatory submissions for _Voydeya_
are currently under review in additional countries.  

**PNH**

PNH is a rare, chronic, progressive and potentially life-threatening blood disorder.
It is characterised by red blood cell destruction within blood vessels (also known
as intravascular haemolysis) and white blood cell and platelet activation, which
can result in thrombosis (blood clots).^(3-5)

PNH is caused by an acquired genetic mutation that may happen any time after birth
and results in the production of abnormal blood cells that are missing important
protective blood cell surface proteins. These missing proteins enable the complement
system, which is part of the immune system and is essential to the body’s defence
against infection, to ‘attack’ and destroy or activate these abnormal blood cells.
^(3) Living with PNH can be debilitating, and signs and symptoms may include blood
clots, abdominal pain, difficulty swallowing, erectile dysfunction, shortness of
breath, excessive fatigue, anaemia and dark-coloured urine.^(3,9,12)

**Clinically Significant EVH**

EVH, the removal of red blood cells outside of the blood vessels, can sometimes 
occur in PNH patients who are treated with C5 inhibitors.^(13,14) Since C5 inhibition
enables PNH red blood cells to survive and circulate, EVH may occur when these now
surviving PNH red blood cells are marked by proteins in the complement system for
removal by the spleen and liver.^(3,5,7) PNH patients with EVH may continue to experience
anaemia, which can have various causes, and may require blood transfusions.^(13-
16) A small subset of people living with PNH who are treated with a C5 inhibitor
experience clinically significant EVH, which can result in continued symptoms of
anaemia and require blood transfusions.^(3,9-11)

**ALPHA**

ALPHA is a pivotal, global Phase III trial designed as a superiority study to evaluate
the efficacy and safety of _Voydeya_ as an add-on to C5 inhibitor therapy _Soliris_
or _Ultomiris_ in patients with PNH who experience clinically significant EVH. In
the double-blind, placebo-controlled, multiple-dose trial, patients were enrolled
and randomised to receive _Voydeya_ or placebo (2:1) in addition to their ongoing
_Soliris_ or _Ultomiris_ therapy for 12 weeks. A prespecified interim analysis was
performed once 63 randomised patients had completed 12 weeks of the primary evaluation
period or discontinued treatment as of 28 June 2022. At 12 weeks, patients on placebo
plus a C5 inhibitor were switched to _Voydeya _plus _Soliris_ or _Ultomiris_, and
patients on _Voydeya_ plus _Soliris or_ _Ultomiris_ remained on treatment for an
additional 12 weeks. Patients who completed both treatment periods (24 weeks) had
the option to participate in a two-year long-term extension period and continue 
to receive _Voydeya_ in addition to _Soliris_ or _Ultomiris_. The open-label period
of the study is ongoing.^(1,17)

**_Voydeya_** **(danicopan)**

_Voydeya_ (danicopan) is a first-in-class oral Factor D inhibitor. The medication
works by selectively inhibiting Factor D, a complement system protein that plays
a key role in the amplification of the complement system response. When activated
in an uncontrolled manner, the complement cascade over-responds, leading the body
to attack its own healthy cells. _Voydeya_ has been granted Breakthrough Therapy
designation by the US Food and Drug Administration and PRIority MEdicines (PRIME)
status by the European Medicines Agency. _Voydeya_ has also been granted Orphan 
Drug Designation in the US, EU and Japan for the treatment of PNH.

_Voydeya_ is approved in Japan for certain adults with PNH in combination with C5
inhibitor therapy.

Alexion is also evaluating _Voydeya_ as a potential monotherapy for geographic atrophy
in a Phase II clinical trial.

_Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare
diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc._

**References**

1.   Lee JW, et al. Addition of danicopan to ravulizumab or eculizumab in patients
with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular
haemolysis (ALPHA): a double-blind, randomised, phase 3 trial. _The Lancet Haematology._
2023;10(12):E955-E965.

2.   Kulasekararaj AG, et al. Prevalence of clinically significant extravascular
hemolysis in stable C5 inhibitor-treated patients with PNH and its association with
disease control, quality of life and treatment satisfaction. Presented at: European
Hematology Association (EHA) Hybrid Congress. 8-11 June 2023; Frankfurt, Germany.
Abs PB2056.

3.   Brodsky RA. Paroxysmal nocturnal hemoglobinuria. _Blood_. 2014;124(18):2804-
2811.

4.   Griffin M, et al. Significant hemolysis is not required for thrombosis in paroxysmal
nocturnal hemoglobinuria. _Haematologica_. 2019;104(3):E94-E96.

5.   Hillmen P, et al. The Complement inhibitor eculizumab in paroxysmal nocturnal
hemoglobinuria. _N Engl J Med_. 2006;355(12):1233-1243.

6.   Lee JW, et al. The role of the alternative pathway in paroxysmal nocturnal 
hemoglobinuria and emerging treatments. _Expert Rev Clin Pharmacol_. 2022;15(7):
851-861.

7.   Kulasekararaj AG, et al. Long-term safety and efficacy of ravulizumab in patients
with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 
3 studies. _Eur J Haematol_. 2022;109(3):205-214.

8.   Kulasekararaj AG, et al. P812: Long-term complement inhibition and survival
outcomes in Patients with paroxysmal nocturnal hemoglobinuria: an interim analysis
of the ravulizumab clinical trials. _HemaSphere_. 2022;6(Suppl):706-707.

9.   Kulasekararaj AG, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-
experienced adult patients with PNH: the 302 study. _Blood_. 2019;133(6):540-549.

10.  Lee JW, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with 
PNH naive to complement inhibitors: the 301 study. _Blood_. 2019;133(6):530-539.

11.  Röth A, et al. Transfusion requirements in adult patients with paroxysmal nocturnal
hemoglobinuria naive to complement inhibitors receiving ravulizumab and eculizumab:
results from a phase 3 non-inferiority study [abstract]. ECTH 2019. Glasgow, UK 
ed. Glasgow, UK2019.

12.  Hillmen P, et al. Effect of the complement inhibitor eculizumab on thromboembolism
on patients with paroxysmal nocturnal hemoglobinuria. _Blood_. 2007;110(12):4123-
4128.

13.  Brodsky RA. A complementary new drug for PNH. _Blood_. 2020;135(12):884-885.

14.  Risitano AM, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria:
time for proximal complement inhibition? A position paper from the SAAWP of the 
EBMT. _Front Immunol_. 2019;10:1157.

15.  Berentsen S, et al. Novel insights into the treatment of complement-mediated
hemolytic anemias. _Ther Adv Hematol._ 2019;10:2040620719873321.

16.  Kulasekararaj AG, et al. Monitoring of patients with paroxysmal nocturnal hemoglobinuria
on a complement inhibitor. _Am J Hematol._ 2021;96(7):E232-E235. 

17.  ClinicalTrials.gov. Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal
Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular
Hemolysis (EVH)(ALPHA). NCT Identifier: NCT04469465. Accessed February 2024.

Share on:
